Rheumatology Advance Access originally published online on September 24, 2008
Rheumatology 2009 48(1):49-52; doi:10.1093/rheumatology/ken369
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide
1Newark Beth Israel Medical Center, Newark and 2Saint Barnabas Medical Center, Livingston, NJ, USA.
Correspondence to: I. Sabnani, Division of Hematology/Oncology, Newark Beth Israel Medical Center, Newark, NJ 07112, USA. E-mail: isabnani{at}sbhcs.com
 |
Abstract |
|---|
Objective. Scleroderma-related interstitial lung disease (SSc-ILD) has limited therapeutic options due to unclear pathogenesis. Recently, PDGF receptor (PDGFR) amplification has been postulated to cause fibrosis. We hypothesized that a combination of immunosuppressive agents, e.g. cyclophosphamide (CYC) and imatinib (PDGFR inhibitor), might be useful for treating SSc-related ILD. Our objective was to evaluate the safety and efficacy of this combination therapy in scleroderma-related pulmonary disease.
Methods. Five patients with advanced SSc-ILD underwent comprehensive cardiopulmonary evaluation, followed by administration of oral imatinib (200 mg/day) and intravenous CYC (500 mg every 3 weeks). Safety was assessed by close monitoring of complete blood count, liver and cardiac functions. Efficacy was evaluated by measuring pulmonary functions at 6 and 12 months.
Results. Of the five patients in the study, four had severe and one had mild restrictive lung disease. All patients tolerated the combination treatment without myelosuppression, deterioration of liver functions or cardiac status. Only one patient had mild fluid overload requiring diuretics. Two patients completed 1 yr of treatment. Only the patient with mild restrictive lung disease showed improvement in pulmonary function.
Conclusion. The combination of intravenous CYC and oral imatinib was well-tolerated without major side effects. Clinical improvement was seen in only the patient with mild restrictive disease. To our knowledge, this is the first study examining the safety, tolerability and efficacy of imatinib in combination with CYC in scleroderma-related pulmonary disease. Large prospective trials are needed to further determine optimal timing, dose and duration of this regimen.
KEY WORDS: Scleroderma-related interstitial lung disease, Treatment of interstitial lung disease, Imatinib, Intravenous cyclophosphamide in interstitial lung disease, Anti-fibrotic therapy, Pulmonary arterial hypertension, PDGF receptor inhibitor, Systemic sclerosis, Imatinib
Submitted 19 March 2008;
revised version accepted 12 August 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. H. W. Distler and O. Distler Imatinib as a novel therapeutic approach for fibrotic disorders Rheumatology, January 1, 2009; 48(1): 2 - 4. [Full Text] [PDF]
|
|